STERIS plc (STE) 10-Year Financial Performance & Capital Metrics

STE • • Industrial / General

HealthcareMedical DevicesDiagnostic & Imaging EquipmentMedical Imaging Systems

AboutSTERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.Show more

Revenue $5.46B +6.2%
EBITDA $1.34B -4.2%
Net Income $615M +62.5%
EPS (Diluted) 6.20 +62.7%
Gross Margin 44.01% +2.0%
EBITDA Margin 24.6% -9.8%
Operating Margin 15.87% -2.4%
Net Margin 11.26% +53.0%
ROE 9.51% +55.9%
ROIC 7.17% +6.4%
Debt/Equity 0.33 -37.9%
Interest Coverage 10.05 +73.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓14 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 12.5%
✓Trading near 52-week high

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y11.43%

5Y12.49%

3Y8.93%

TTM13.54%

Profit (Net Income) CAGR

10Y16.36%

5Y8.56%

3Y36.09%

TTM58.35%

EPS CAGR

10Y10.67%

5Y5.43%

3Y35.72%

TTM59.05%

ROCE

10Y Avg8.05%

5Y Avg8.18%

3Y Avg8.35%

Latest9%

Peer Comparison

Medical Imaging Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
IRMDIRadimed Corporation	1.29B	101.53	67.69	11.71%	26.31%	21.54%	1.36%	0.00
BRKRBruker Corporation	7.47B	49.14	64.66	13.56%	-0.61%	-0.84%	1.82%	1.24
STESTERIS plc	25.94B	264.25	42.62	6.24%	12.07%	9.8%	3%	0.33
FONRFONAR Corporation	114.8M	18.61	15.13	1.43%	7.08%	4.62%	6.49%	0.24
PACBPacific Biosciences of California, Inc.	712.5M	2.36	-2.21	-23.19%	-325.8%	-13.95%		1.33
HYPRHyperfine, Inc.	101.82M	1.24	-2.21	16.84%	-378.17%	-149.05%		0.01
IRIXIRIDEX Corporation	22.69M	1.32	-2.44	-6.17%	-10.04%	-108.67%		2.21
MASS908 Devices Inc.	196.89M	5.44	-2.57	18.72%	-7.17%	-3.03%		0.06

Profit & Loss

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	2.24B	2.61B	2.62B	2.78B	3.03B	3.11B	4.22B	4.54B	5.14B	5.46B
Revenue Growth %	0.21%	0.17%	0%	0.06%	0.09%	0.03%	0.36%	0.07%	0.13%	0.06%
Cost of Goods Sold+	1.34B	1.59B	1.53B	1.61B	1.71B	1.76B	2.34B	2.56B	2.92B	3.06B
COGS % of Revenue	0.6%	0.61%	0.58%	0.58%	0.56%	0.57%	0.55%	0.56%	0.57%	0.56%
Gross Profit+	895.48M	1.03B	1.09B	1.17B	1.32B	1.34B	1.88B	1.98B	2.22B	2.4B
Gross Margin %	0.4%	0.39%	0.42%	0.42%	0.44%	0.43%	0.45%	0.44%	0.43%	0.44%
Gross Profit Growth %	0.16%	0.15%	0.06%	0.08%	0.12%	0.02%	0.4%	0.05%	0.12%	0.08%
Operating Expenses+	682.55M	800.01M	692.86M	763.96M	782.95M	794.73M	1.41B	1.19B	1.38B	1.54B
OpEx % of Revenue	0.3%	0.31%	0.26%	0.27%	0.26%	0.26%	0.33%	0.26%	0.27%	0.28%
Selling, General & Admin	626.71M	682.04M	631.98M	669.94M	716.73M	731.32M	1.32B	1.09B	1.25B	1.33B
SG&A % of Revenue	0.28%	0.26%	0.24%	0.24%	0.24%	0.24%	0.31%	0.24%	0.24%	0.24%
Research & Development	56.66M	59.4M	60.78M	63.04M	65.55M	66.33M	86.66M	98.48M	103.68M	107.65M
R&D % of Revenue	0.03%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%
Other Operating Expenses	-820K	58.57M	103K	30.99M	673K	-2.91M	48K	485K	26.05M	94.2M
Operating Income+	212.93M	226.21M	399.88M	411.02M	537.05M	548.37M	477.81M	791.1M	836.12M	866.64M
Operating Margin %	0.1%	0.09%	0.15%	0.15%	0.18%	0.18%	0.11%	0.17%	0.16%	0.16%
Operating Income Growth %	-0.06%	0.06%	0.77%	0.03%	0.31%	0.02%	-0.13%	0.66%	0.06%	0.04%
EBITDA+	356.67M	414.35M	578.22M	636.95M	734.28M	767.61M	1.03B	1.34B	1.4B	1.34B
EBITDA Margin %	0.16%	0.16%	0.22%	0.23%	0.24%	0.25%	0.24%	0.3%	0.27%	0.25%
EBITDA Growth %	0.12%	0.16%	0.4%	0.1%	0.15%	0.05%	0.34%	0.3%	0.04%	-0.04%
D&A (Non-Cash Add-back)	143.74M	188.14M	178.33M	225.92M	197.24M	219.24M	553.1M	552.9M	565.24M	476.21M
EBIT	214.59M	229.17M	405.61M	414.04M	539.03M	554.71M	456.29M	791.1M	847.16M	882.47M
Net Interest Income+	-41.04M	-41.56M	-44.9M	-41.99M	-38.29M	-30.84M	-83.21M	-110.83M	-133.31M	-77.86M
Interest Income	1.67M	2.96M	5.73M	3.02M	1.99M	6.34M	6.28M	0	11.04M	8.4M
Interest Expense	42.71M	44.52M	50.63M	45.02M	40.28M	37.18M	89.49M	110.83M	144.35M	86.26M
Other Income/Expense	-41.04M	-41.56M	-44.9M	-41.99M	-38.29M	-30.84M	-111.01M	-110.83M	-133.31M	-70.43M
Pretax Income+	171.88M	184.65M	354.98M	369.03M	498.75M	517.53M	366.8M	680.27M	702.81M	796.21M
Pretax Margin %	0.08%	0.07%	0.14%	0.13%	0.16%	0.17%	0.09%	0.15%	0.14%	0.15%
Income Tax+	60.3M	74.02M	63.36M	64.28M	90.89M	120.66M	82.34M	124.07M	149.53M	184.65M
Effective Tax Rate %	0.64%	0.6%	0.82%	0.82%	0.82%	0.77%	0.66%	0.16%	0.54%	0.77%
Net Income+	110.76M	109.97M	290.92M	304.05M	407.66M	397.4M	243.89M	107.03M	378.24M	614.64M
Net Margin %	0.05%	0.04%	0.11%	0.11%	0.13%	0.13%	0.06%	0.02%	0.07%	0.11%
Net Income Growth %	-0.18%	-0.01%	1.65%	0.05%	0.34%	-0.03%	-0.39%	-0.56%	2.53%	0.63%
Net Income (Continuing)	111.58M	110.63M	291.62M	305.08M	407.86M	396.87M	284.46M	556.2M	553.28M	611.56M
Discontinued Operations	0	0	0	0	0	0	-41.59M	-450.38M	-173.2M	4.52M
Minority Interest	15.86M	11.43M	11.34M	7.99M	12.85M	10.48M	12.28M	9.97M	13.18M	12.35M
EPS (Diluted)+	1.56	1.28	3.39	3.56	4.76	4.63	2.48	1.07	3.81	6.20
EPS Growth %	-0.31%	-0.18%	1.65%	0.05%	0.34%	-0.03%	-0.46%	-0.57%	2.56%	0.63%
EPS (Basic)	1.57	1.29	3.42	3.59	4.81	4.66	2.50	1.07	3.83	6.24
Diluted Shares Outstanding	71.18M	86.09M	85.71M	85.47M	85.64M	85.9M	98.33M	100.25M	99.36M	99.07M
Basic Shares Outstanding	70.7M	85.47M	85.03M	84.58M	84.78M	85.2M	97.53M	99.71M	98.79M	98.58M
Dividend Payout Ratio	0.59%	0.85%	0.35%	0.37%	0.3%	0.34%	0.67%	1.71%	0.53%	0.36%

Balance Sheet

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	972.52M	1.02B	989.66M	1.05B	1.22B	1.21B	1.88B	2.01B	2.87B	2B
Cash & Short-Term Investments	248.84M	282.92M	201.53M	220.63M	319.58M	220.53M	348.32M	208.36M	207.02M	171.7M
Cash Only	248.84M	282.92M	201.53M	220.63M	319.58M	220.53M	348.32M	208.36M	207.02M	171.7M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	471.52M	483.45M	528.07M	564.83M	586.48M	609.41M	799.04M	864.99M	1.01B	1.04B
Days Sales Outstanding	76.88	67.54	73.57	74.1	70.63	71.58	69.06	69.6	71.62	69.79
Inventory	192.79M	197.84M	205.73M	208.24M	263.54M	315.07M	575M	604.41M	674.53M	581.33M
Days Inventory Outstanding	52.39	45.51	49.17	47.29	56.22	65.18	89.67	86.33	84.3	69.42
Other Current Assets	0	0	0	0	0	0	0	154.41M	979.25M	203.77M
Total Non-Current Assets+	4.37B	3.91B	4.21B	4.02B	4.22B	5.36B	9.54B	8.81B	8.19B	8.15B
Property, Plant & Equipment	1.06B	915.91M	1.01B	1.03B	1.24B	1.39B	1.74B	1.8B	1.94B	2.11B
Fixed Asset Turnover	2.10x	2.85x	2.59x	2.70x	2.44x	2.24x	2.43x	2.52x	2.65x	2.58x
Goodwill	2.16B	2.23B	2.43B	2.32B	2.36B	3.03B	4.4B	3.88B	4.07B	4.1B
Intangible Assets	1.12B	724.89M	726.98M	604.61M	565.47M	898.41M	3.33B	2.08B	2.12B	1.85B
Long-Term Investments	0	0	0	0	0	0	0	0	0	14.3M
Other Non-Current Assets	29.63M	34.55M	39.39M	60.21M	51.58M	52.72M	70.66M	1.06B	66.2M	68.75M
Total Assets+	5.35B	4.92B	5.2B	5.07B	5.44B	6.57B	11.42B	10.82B	11.06B	10.15B
Asset Turnover	0.42x	0.53x	0.50x	0.55x	0.56x	0.47x	0.37x	0.42x	0.46x	0.54x
Asset Growth %	1.55%	-0.08%	0.06%	-0.02%	0.07%	0.21%	0.74%	-0.05%	0.02%	-0.08%
Total Current Liabilities+	400.61M	381.58M	398.46M	465.2M	503.61M	577.92M	922.22M	861.84M	931.13M	1.02B
Accounts Payable	139.57M	133.48M	135.87M	152.91M	149.34M	156.95M	225.74M	264.17M	251.72M	280.77M
Days Payables Outstanding	37.92	30.71	32.47	34.73	31.86	32.47	35.21	37.73	31.46	33.53
Short-Term Debt	0	0	0	0	0	0	142.88M	60M	85.94M	125M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	172.49M	139.46M	207.6M	219.01M	243.94M	271.39M	323.65M	331.69M	418.35M	447.01M
Current Ratio	2.43x	2.67x	2.48x	2.27x	2.43x	2.10x	2.04x	2.33x	3.08x	1.96x
Quick Ratio	1.95x	2.15x	1.97x	1.82x	1.91x	1.55x	1.41x	1.63x	2.36x	1.39x
Cash Conversion Cycle	91.34	82.34	90.26	86.67	94.99	104.29	123.53	118.2	124.46	105.68
Total Non-Current Liabilities+	1.91B	1.73B	1.58B	1.42B	1.52B	2.11B	3.96B	3.87B	3.82B	2.51B
Long-Term Debt	1.57B	1.48B	1.32B	1.18B	1.15B	1.65B	2.95B	3.02B	3.12B	1.92B
Capital Lease Obligations	0	0	0	0	114.11M	129.67M	155.06M	139.56M	145.83M	124.64M
Deferred Tax Liabilities	254.82M	171.81M	159.97M	151.04M	164.07M	236.86M	780.62M	617.54M	479.69M	403.65M
Other Non-Current Liabilities	84.3M	82.67M	108.6M	87.81M	90.35M	88.01M	75.58M	97.07M	71.55M	61.89M
Total Liabilities	2.31B	2.11B	1.98B	1.89B	2.02B	2.68B	4.88B	4.73B	4.75B	3.53B
Total Debt+	1.57B	1.48B	1.32B	1.18B	1.28B	1.8B	3.28B	3.25B	3.38B	2.2B
Net Debt	1.32B	1.2B	1.11B	962.59M	964.86M	1.58B	2.93B	3.04B	3.18B	2.03B
Debt / Equity	0.52x	0.53x	0.41x	0.37x	0.38x	0.46x	0.50x	0.53x	0.54x	0.33x
Debt / EBITDA	4.40x	3.57x	2.28x	1.86x	1.75x	2.35x	3.18x	2.42x	2.41x	1.64x
Net Debt / EBITDA	3.70x	2.89x	1.93x	1.51x	1.31x	2.06x	2.84x	2.26x	2.27x	1.51x
Interest Coverage	4.99x	5.08x	7.90x	9.13x	13.33x	14.75x	5.34x	7.14x	5.79x	10.05x
Total Equity+	3.04B	2.81B	3.22B	3.19B	3.42B	3.89B	6.54B	6.09B	6.32B	6.62B
Equity Growth %	1.83%	-0.08%	0.14%	-0.01%	0.07%	0.14%	0.68%	-0.07%	0.04%	0.05%
Book Value per Share	42.69	32.64	37.54	37.27	39.91	45.30	66.56	60.72	63.56	66.78
Total Shareholders' Equity	3.02B	2.8B	3.21B	3.18B	3.41B	3.88B	6.53B	6.08B	6.3B	6.6B
Common Stock	2.15B	2.09B	2.05B	2B	1.98B	2B	4.74B	4.49B	4.54B	4.42B
Retained Earnings	939.46M	954.15M	1.15B	1.34B	1.66B	1.94B	2B	1.91B	2.09B	2.48B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-68.16M	-240.7M	11.69M	-159.78M	-235.46M	-61.24M	-209.81M	-320.71M	-328.66M	-292.34M
Minority Interest	15.86M	11.43M	11.34M	7.99M	12.85M	10.48M	12.28M	9.97M	13.18M	12.35M

Cash Flow

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	254.68M	424.09M	457.63M	539.5M	590.56M	689.64M	684.81M	756.95M	973.27M	1.15B
Operating CF Margin %	0.11%	0.16%	0.17%	0.19%	0.19%	0.22%	0.16%	0.17%	0.19%	0.21%
Operating CF Growth %	0.04%	0.67%	0.08%	0.18%	0.09%	0.17%	-0.01%	0.11%	0.29%	0.18%
Net Income	111.58M	110.63M	291.62M	304.75M	407.86M	396.87M	242.87M	105.81M	380.08M	616.07M
Depreciation & Amortization	143.74M	188.14M	178.33M	225.92M	197.24M	219.24M	553.1M	552.9M	565.24M	476.21M
Stock-Based Compensation	16.15M	18.79M	22.19M	23.96M	23.81M	25.97M	57.66M	38.95M	56.53M	57.4M
Deferred Taxes	704K	31.27M	-24.72M	-6.62M	9.44M	4.24M	-106.62M	-185.91M	-131.41M	-76.55M
Other Non-Cash Items	3.03M	132.45M	49.36M	-18.84M	2.02M	24.32M	87.07M	495.22M	248.91M	8.43M
Working Capital Changes	-20.53M	-57.2M	-59.15M	10.34M	-49.81M	19.01M	-149.28M	-250.02M	-146.08M	66.51M
Change in Receivables	-31.56M	-48.14M	-37.73M	-48.49M	-17.87M	12.08M	-51.97M	-133.3M	-128.07M	-28.82M
Change in Inventory	1.81M	-12.83M	-5.18M	-14.18M	-39.14M	3.77M	-102.92M	-123.92M	-37.45M	73.07M
Change in Payables	5.25M	6.88M	563K	21.24M	-2.78M	-7.21M	14.89M	53.34M	-18.96M	33.59M
Cash from Investing+	-729.58M	-104.25M	-203.83M	-213.22M	-319.74M	-1.15B	-666.56M	-383.33M	-887.36M	388.77M
Capital Expenditures	-126.41M	-172.9M	-165.46M	-189.72M	-214.52M	-239.26M	-287.56M	-361.97M	-360.33M	-370.09M
CapEx % of Revenue	0.06%	0.07%	0.06%	0.07%	0.07%	0.08%	0.07%	0.08%	0.07%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	844K	4.85M	-989K	-13.29M	4.16M	-1.82M	1.74M	14.59M	7.38M	9.2M
Cash from Financing+	560.29M	-267.1M	-356.18M	-294.79M	-163.15M	345.62M	115.83M	-498.72M	-85.19M	-1.57B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-65.2M	-93.19M	-102.93M	-112.5M	-123.03M	-133.84M	-163.17M	-183.5M	-200.57M	-219.88M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	12.98M	-1.01M	5.67M	11.29M	37.63M	9.56M	-37.41M	-437K	5.66M	23.26M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	128.27M	251.19M	292.18M	349.79M	376.04M	450.38M	397.25M	394.98M	612.95M	778M
FCF Margin %	0.06%	0.1%	0.11%	0.13%	0.12%	0.14%	0.09%	0.09%	0.12%	0.14%
FCF Growth %	-0.2%	0.96%	0.16%	0.2%	0.08%	0.2%	-0.12%	-0.01%	0.55%	0.27%
FCF per Share	1.80	2.92	3.41	4.09	4.39	5.24	4.04	3.94	6.17	7.85
FCF Conversion (FCF/Net Income)	2.30x	3.86x	1.57x	1.77x	1.45x	1.74x	2.81x	7.07x	2.57x	1.87x
Interest Paid	37.16M	42.8M	48.66M	0	0	0	84.7M	108.47M	142.17M	89.4M
Taxes Paid	60.88M	78.01M	85.63M	0	0	0	138.38M	254.66M	271.27M	273.61M

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	5.39%	3.76%	9.65%	9.5%	12.35%	10.87%	4.67%	1.69%	6.1%	9.51%
Return on Invested Capital (ROIC)	5.43%	4.06%	7.19%	7.27%	9.44%	8.34%	4.79%	6.38%	6.74%	7.17%
Gross Margin	40%	39.28%	41.71%	42.23%	43.55%	43.22%	44.59%	43.66%	43.17%	44.01%
Net Margin	4.95%	4.21%	11.1%	10.93%	13.45%	12.79%	5.77%	2.36%	7.36%	11.26%
Debt / Equity	0.52x	0.53x	0.41x	0.37x	0.38x	0.46x	0.50x	0.53x	0.54x	0.33x
Interest Coverage	4.99x	5.08x	7.90x	9.13x	13.33x	14.75x	5.34x	7.14x	5.79x	10.05x
FCF Conversion	2.30x	3.86x	1.57x	1.77x	1.45x	1.74x	2.81x	7.07x	2.57x	1.87x
Revenue Growth	21%	16.71%	0.28%	6.19%	8.94%	2.53%	35.91%	7.41%	13.28%	6.24%

Revenue by Segment

	2019	2020	2021	2022	2023	2024	2025
Product	1.3B	1.4B	1.44B	2.56B	2.79B	2.76B	2.87B
Product Growth	-	8.24%	2.91%	77.08%	8.96%	-0.77%	3.89%
Service	1.49B	1.63B	1.66B	2.03B	2.17B	2.37B	2.59B
Service Growth	-	9.55%	2.20%	21.92%	7.08%	9.31%	8.98%

Revenue by Geography

	2019	2020	2021	2022	2023	2024	2025
UNITED STATES	1.98B	2.21B	2.23B	3.23B	3.59B	3.75B	4.01B
UNITED STATES Growth	-	11.88%	0.69%	44.98%	11.08%	4.60%	6.83%
Other foreign locations	748.57M	755.35M	808.58M	1.27B	1.3B	1.3B	1.34B
Other foreign locations Growth	-	0.91%	7.05%	57.58%	1.78%	0.59%	3.07%
IRELAND	-	63.82M	71.91M	82.01M	74.46M	82.69M	107.32M
IRELAND Growth	-	-	12.67%	14.05%	-9.20%	11.06%	29.78%
UNITED KINGDOM	56.78M	-	-	-	-	-	-
UNITED KINGDOM Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

STERIS plc (STE) has a price-to-earnings (P/E) ratio of 42.6x. This suggests investors expect higher future growth.

Growth & Financials

STERIS plc (STE) reported $5.70B in revenue for fiscal year 2025. This represents a 305% increase from $1.41B in 2012.

STERIS plc (STE) grew revenue by 6.2% over the past year. This is steady growth.

Yes, STERIS plc (STE) is profitable, generating $688.5M in net income for fiscal year 2025 (11.3% net margin).

Dividend & Returns

Yes, STERIS plc (STE) pays a dividend with a yield of 0.84%. This makes it attractive for income-focused investors.

STERIS plc (STE) has a return on equity (ROE) of 9.5%. This is below average, suggesting room for improvement.

STERIS plc (STE) generated $961.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...